Exclusive Investment Opportunities

We’ve filtered and vetted and conducted due diligence on hundreds of deals and come up with a selection of business opportunities that offer above-average risk adjusted yields.

If you want to find out more, click the button under each opportunity, or simply email James Spurway directly…Wishing you a successful and prosperous 2020.

BioTech/BioPharma – Breakthrough drug to treat Multidrug Resistant Cancer Patients and Patent filed for COVID19 Treatment (not a vaccine)

Raising $4M on a Convertible Note @8% p.a., convertible into shares of an OTC Pink Slip Company – Minimum Investment $100,000

About Sunshine Biopharma

Sunshine Biopharma Inc. (OTC Pink: SBFM) is a pharmaceutical company focused on the research, development and commercialization of natural supplements and treatments of various forms of cancer, and more recently for COVID19.

  • In December 2018, they completed the development of a new dietary supplement which we trademarked Essential 9 TM. This dietary supplement is an over-the-counter tablet comprised of the nine amino acids which the human body cannot make. Essential 9 TM has been authorized for marketing by Health Canada under NPN 80089663. On March 12, 2019 Essential 9 TM became available for sale on Amazon.ca and on March 23, 2019 they recorded our first revenues of Essential 9 TM sales.
  • In November 2019, the Company received Health Canada approval for a new Calcium-Vitamin D supplement. Health Canada issued NPN 80093432 through which it authorized the Company to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin DTM. It will become available for purchase on Amazon in the 3rd quarter of 2020.
  • In June 2020, the company filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19.
  • Sunshine’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.
  • “The causative agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human
    cells by cleaving them from two overlapping viral ‘polyproteins,’ pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves the viral ‘polyproteins’ at a number of specific sites thereby generating a multi-subunit protein complex termed ‘viral replicase-transcriptase’. Because of its functional indispensability in viral replication, Mpro is an attractive drug target for the development of a treatment for COVID-19 and other Coronavirus infections,” said Dr. Slilaty.
  • They have also designed and synthesized a new compound, Adva-27a, targeted for multidrug resistant cancer. Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935. In our recently completed preclinical studies [ANTICANCER RESEARCH 32:4423-4432 (2012)], Adva-27a has proven to be remarkably effective against multidrug resistant cancer cells including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma. Sunshine Biopharma’s Adva-27a is the only compound known that can kill multidrug resistant cancer cells.
5/5

AI/Robo-Advisory/Crypto/ – A JV partnership with a well known white hat hacker,  internet security advisor, trading bot developer and systematic trading strategy developer

Raising $1M on a Convertible Note @12%p.a., convertible into shares of a Singapore Limited company, or if required, an SPV in a jurisdiction of preferred choice – Minimum Investment $100,000

 

  • 18 months track record of trading strategies having at least a 66%:34% winning to losing execution ratio.
  • Strategies can be followed online in real time.
  • Strategies work on all asset classes and even work on Sports Betting
  • Product pricing will follow an Saas subscription + API “pay to play” model
  • Break Even point in less than 12 months
5/5

Global Resources/Blockchain – World Class Team meets World’s First Tokenization of in-ground Gold Assets

Raising EUR 150,000,000 via a Private Placement if Interest Bearing Notes (BONDS) @9%p.a. and 12%p.a., backed by real gold – Minimum Investment EUR 150,000

 
1. High Yield Smart Carbon Logistics Bond (backed by real gold)
Yield: 12% coupon pa, paid quarterly
Kicker: None
Term: 5 years (option to extend for 2 more years – if so Bondholders receive a 3% capital bonus on maturity)
Listing: Clearstream out of Luxembourg
Currency: EUR$ or USD$ or AUD$ (currently set for EUR$)
Minimum Investment: EUR$150,000 or USD$200,000 or AUD$300,000
Issue: EUR$75 million or USD$100 million or AUD$150 million
Loan to Value: Under 14%
Securities: US production supply chain re-start – cash, inventory, receivables, plant & equipment, land, proven recoverable mineral rights and $60 million in SEC compliant gold securities to guarantee coupon performance, 12 months coupon held by Trustee in reserve – circa 75 to 100%+ of new capital remains on the balance sheet as LIQUID CURRENT ASSETS.
 
2. Gold Bond (backed by real gold)
Yield: 9% coupon pa, paid quarterly
Kicker: % increase in the spot gold price paid at maturity, with no downside price risk
Term: 5 years (option to extend for 2 more years – if so Bondholders receive a 3% capital bonus on maturity)
Listed: On Clearstream out of Luxembourg
Currency: EUR$ or USD$ or AUD$ (currently set for EUR$)
Minimum Investment: EUR$150,000 or USD$200,000
Issue: EUR$75 million or USD$100 million or AUD$150 million
Loan to Value: Under 40% base on production gold asset before backstop gold securities

Securities: US production stage gold assets re-start – cash, inventory, receivables, plant & equipment, land, proven recoverable mineral rights and 100% backed by SEC compliant gold securities to guarantee bond performance, 12 months coupon held by Trustee in reserve.

 
Universal Fundamentals
1. No product has development or path to market risks
2. Exceptionally strong underlying assets and management (Management have previously built the world’s best underground mining company and world’s largest gold mining company – see attached execution capabilities statement)
3. Each bond is professionally managed by an independent professional Trustee that administers the bond and holds all the debt, equity and securities on behalf of Bondholders – Management only get back the keys after obligations to Bondholders have been met in full.
4. High yield liquidity via Clearstream listing
5. Insurer is effectively taking on the capital risk via the gold securities collateral backstop
6 Market level placement fees
 
The three standout fundamentals are:
(1) Management and asset quality;
(2) Gold securities backstop; and
(3) The Trustee holds everything including a 12 month reserve, this provides full visibility with NO risk of a surprise default event and full control with NO legal arguments over the assets in the event of a default event.
5/5

DeepTech/Quantum – Multiproduct hardware+software solution that is more efficient than existing Building-integrated photovoltaics and turns building clusters into smart cities.

Raising $5M on a Convertible Note @8% p.a., convertible into shares of an UK Limited Company at the pre-IPO stage – Minimum investment $100,000

Freschfield’s founder, Dr Allen St James,  has since 1995 been on the cutting edge of clean energy technology evolution.

  • The main problem the industry faces today is that there are no optimum-efficiency carbon-free energy systems.
  • Freschfield’s solution was to  invent advanced smart skins for sustainable buildings worldwide, implementing a sophisticated quantum technology that offers both a transparent and opaque solutions with higher efficiency than all current BIPV technologies.
  • Their technology makes it possible for the first time in history to actually integrate smart sustainable energy systems into the structural envelope of a building, thereby making any part of the structure both intelligent and net energy positive.
  • They have signed LOI’s and MOU’s for large scale solar farm projects with Scottish and Southern Energy (SSE) in the UK, and Parkway Corporation in the USA.
  • R&D strategic partners are MIT, CALTECH, STANFORD and UNIVERSITY OF LEEDS. 
5/5

DeepTech/CleanTech – Proprietary Organic Oil Recovery process requires zero CAPEX and between 90-120 days to utilise in-well bacteria to release up to 90% more oil reserves than were previously possible.

Raising $5M on a Convertible Note @8% p.a., convertible into shares of an UK Limited Company at the pre-IPO stage – Minimum investment $100,000

 

Tigbourne Capital Ltd (“Tigbourne”) and Titan Oil Recovery, Inc. (“Titan”) wish to set up Tigbourne Oil Recovery Ltd (“TOR”) with sophisticated investors to use the Titan Process.

  • TOR will acquire oil fields opportunistically anywhere in the globe to capture excess
    economic benefits from the Titan process
  • TOR will be initially funded by at least $5 million of debt using its balance sheet, together with debt financing to acquire strategic oil fields or engage in profit sharing agreements.
  • Risky Exploration and Drilling are not required.
  • Acquisitions will be based on known reserves that can be enhanced by the Titan Process.
5/5
Don't Leave Yet!
Take advantage of a FREE 15 Minute Consultation About Your Business
We respect your privacy.